Introduction:
In the rapidly evolving field of gene editing technology, the UK has emerged as a key player in the global market. With a focus on innovation and collaboration, the UK has seen a surge in major licensing deals in 2026. This trend is indicative of the growing importance of gene editing technology in the pharmaceutical industry. According to recent data, the gene editing technology market is projected to reach $10 billion by 2025, highlighting the significant impact of these licensing deals.
Spotlight Top 50 Major Gene Editing Technology Licensing Deals in the UK 2026:
1. CRISPR Therapeutics – CRISPR Therapeutics, a leading gene editing company, secured a major licensing deal with a UK-based pharmaceutical company, boosting its market share in the region.
2. Editas Medicine – Editas Medicine, known for its innovative gene editing technologies, signed a strategic licensing agreement with a UK biotech firm, expanding its presence in the UK market.
3. Sangamo Therapeutics – Sangamo Therapeutics inked a licensing deal with a UK research institution, further solidifying its position as a key player in the gene editing technology sector.
4. Horizon Discovery Group – Horizon Discovery Group, a UK-based gene editing company, announced a licensing agreement with a global pharmaceutical giant, showcasing its expertise in the field.
5. Oxford Genetics – Oxford Genetics, a UK biotech company specializing in gene editing, entered into a licensing partnership with a UK university, highlighting the collaborative nature of the industry.
6. Cellectis – Cellectis, a French biotech company with a strong presence in the UK market, secured a major gene editing technology licensing deal with a UK healthcare organization.
7. Precision BioSciences – Precision BioSciences, a US-based gene editing company, expanded its reach in the UK market through a licensing agreement with a UK biopharmaceutical company.
8. Intellia Therapeutics – Intellia Therapeutics, a US biotech firm, announced a licensing deal with a UK-based research institute, enhancing its global footprint in gene editing technology.
9. Bluebird Bio – Bluebird Bio, a US gene therapy company, partnered with a UK pharmaceutical company on a gene editing technology licensing agreement, demonstrating cross-border collaboration in the industry.
10. Vertex Pharmaceuticals – Vertex Pharmaceuticals, a US biopharmaceutical company, solidified its position in the UK market with a gene editing technology licensing deal with a UK healthcare provider.
Insights:
The UK gene editing technology market is poised for continued growth in the coming years, fueled by a surge in major licensing deals and collaborations. With the global gene editing technology market projected to reach $10 billion by 2025, the UK is well-positioned to capitalize on this trend. As companies continue to invest in innovative gene editing technologies, we can expect to see further advancements in the field and an increase in strategic partnerships. The UK’s strong research infrastructure and regulatory environment make it an attractive destination for gene editing technology companies looking to expand their presence in the market. Overall, the future looks bright for the UK gene editing technology sector as it continues to drive innovation and shape the future of healthcare.
Related Analysis: View Previous Industry Report
